{"id":305061,"date":"2026-03-24T00:00:00","date_gmt":"2026-03-24T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2024-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-2\/"},"modified":"2026-04-25T05:08:40","modified_gmt":"2026-04-25T05:08:40","slug":"dlsfon0010-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-landscape-forecast","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0010-2026-biopharma-squamous-cell-carcinoma-of-the-head-and-neck-landscape-forecast-disease-landscape-forecast\/","title":{"rendered":"Squamous Cell Carcinoma of the Head and Neck &#8211; Landscape &#038; Forecast &#8211; Disease Landscape &#038; Forecast (G7)"},"content":{"rendered":"<p>Squamous cell carcinoma of the head and neck (<abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>) is the seventh most commonly diagnosed cancer. It encompasses a spectrum of heterogeneous tumors originating at multiple sites in the head and neck. Chemotherapy remains standard in locoregionally advanced <abbr title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>, but the recent approval of perioperative pembrolizumab is expected to reshape early-stage management. Targeted therapies are frequently prescribed to patients with recurrent or metastatic disease. The usual treatment algorithm starts with a <abbr data-abbreviation-entity=\"5174\" title=\"programmed cell death-1\">PD-1<\/abbr> inhibitor (pembrolizumab [Keytruda]) for recurrent or metastatic disease, followed by an <abbr data-abbreviation-entity=\"5565\" title=\"epidermal growth factor receptor\">EGFR<\/abbr>-targeting agent (cetuximab [Erbitux]) after progression. The expected approval of petosemtamab (in combination with pembrolizumab), will significantly impact treatment in the recurrent and metastatic settings during the 2024-2034 forecast period. Ficlatuzumab (in combination with cetuximab), amivantamab (Rybrevant Faspro) and petosemtamab in later-line treatment are expected to further reshape the treatment landscape for patients with recurrent and metastatic disease. The approval of toripalimab (Loqtorzi) is setting a new treatment paradigm for nasopharyngeal carcinoma (<abbr data-abbreviation-entity=\"10822\" title=\"nasopharyngeal carcinoma\">NPC<\/abbr>)<abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">,<\/abbr> with strong adoption anticipated. The recently approved penpulimab is expected to see more limited uptake among these patients.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>What are the sizes of the clinically and commercially relevant drug-treatable populations in this market, and how will drug-treatment rates change over time?<\/li>\n<li>What barriers and drivers will influence the adoption of <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr> therapies during the forecast period?<\/li>\n<li>How will the entry of new pembrolizumab-based combinations, such as petosemtamab, impact the treatment for first-line recurrent or metastatic <abbr data-abbreviation-entity=\"4959\" title=\"squamous cell carcinoma of the head and neck\">SCCHN<\/abbr>?<\/li>\n<li>What are the key market drivers and constraints, and how is the market expected to evolve over the next 10 years?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n","protected":false},"template":"","class_list":["post-305061","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-solid-tumors","biopharma-therapy-areas-squamous-cell-carcinoma-of-the-head-and-neck","biopharma-geography-us","biopharma-date-2609"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305061","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":10,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305061\/revisions"}],"predecessor-version":[{"id":575175,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/305061\/revisions\/575175"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=305061"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}